Virax Biolabs Group Stock (NASDAQ:VRAX)
Previous Close
$2.85
52W Range
$2.50 - $21.75
50D Avg
$3.13
200D Avg
$5.39
Market Cap
$498.29K
Avg Vol (3M)
$1.83M
Beta
1.35
Div Yield
-
VRAX Company Profile
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.